Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

700.98
+27.954.15%
Number of Gainers:93
Number of Losers:48
Number of Flat:13
PE:- -
High:701.76
Open:676.45
Low:676.45
Close:673.03
Volume:618.04M
Turnover:15.17B
Market Cap:489.04B
Float Cap:371.70B

Loading ...

Werewolf Therapeutics Shares Leap on Reverse Merger, Asset Sale

Dow Jones
·
Aug 21

Kanzhun Limited Expected to Post Earnings of Cny2.12 a Share - Earnings Preview

Reuters
·
Aug 21

Latham Group Enters New USD 375 Million Senior Secured Credit Facility with Jefferies Finance as Agent

Reuters
·
Aug 21

RenovoRx regains compliance with Nasdaq

TIPRANKS
·
Aug 21

Latham Group - Credit Agreement Includes $75 Mln Revolver and $300 Mln Term Loan Facility - SEC Filing

THOMSON REUTERS
·
Aug 21

Latham Group - Proceeds Used to Repay and Terminate Prior Credit Agreement Dated February 23, 2022 - SEC Filing

THOMSON REUTERS
·
Aug 21

Crypto Stocks Keep Climbing in Tandem with Bitcoin

Dow Jones
·
Aug 21

Werewolf More than Doubles on Ambros Therapeutics Merger

Reuters
·
Aug 21

Dermata Therapeutics announces Tome Foundational Treatment open to preorders

TIPRANKS
·
Aug 21

Coinbase Stock Forecast: COIN Price Breaks Above $180, Poised to Rise Over 20% Further

TradingKey
·
Aug 21

RenovoRx Regains Compliance with NASDAQ Minimum Bid Price Requirement

THOMSON REUTERS
·
Aug 21

Werewolf Therapeutics Announces USD 150 Million Oversubscribed Private Placement of Shares, Pre-Funded Warrants

Reuters
·
Aug 21

Werewolf Therapeutics Agrees to Merge with Ambros Therapeutics in All-Stock Deal

Reuters
·
Aug 21

Analysts Offer Insights on Financial Companies: Robinhood (HOOD) and US Bancorp (USB)

TIPRANKS
·
Aug 21

Werewolf Therapeutics - Combined Company to Operate as Ambros Therapeutics, to Trade as Ambx on NASDAQ

THOMSON REUTERS
·
Aug 21

Werewolf Therapeutics: Stockholders of Ambros Will Receive Newly Issued Shares of Co's Stock Stock Pursuant to a Formula Set Forth in Deal Agreement

THOMSON REUTERS
·
Aug 21

Werewolf Therapeutics - Deal Expected to Close by Q1 2027 Subject to Approvals

THOMSON REUTERS
·
Aug 21

Werewolf Therapeutics - Stockholders to Own 6.8%, Ambros Stockholders 71.7%, Private Placement Investors 21.5% of Combined Co

THOMSON REUTERS
·
Aug 21

Werewolf Therapeutics: Ambros Expects Combined Co to be Fully Funded Through Topline Results from Pivotal Crps-Rise Phase 3 Clinical Trial

THOMSON REUTERS
·
Aug 21

Werewolf Therapeutics: Exchange is Based on Implied Value of Ambros of $500 Mln (Before Private Placement) and Implied Value of Co of $47.5 Mln

THOMSON REUTERS
·
Aug 21